Experimental nanoparticle boosts radiation against esophageal cancer
NCT ID NCT04615013
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation to destroy cancer cells. It is given alongside standard chemotherapy for people with stage II–III esophageal adenocarcinoma. The main goals are to find the safest dose and see if the combination is tolerable. Only 24 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBTXR3 (a nanoparticle drug activated by radiation)
What this could lead to
If it works, this could point toward a new way to enhance radiation and chemotherapy for esophageal cancer, potentially improving tumor control.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, focused on safety and dosing. It may not lead to a proven treatment, and side effects from the combination therapy are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact